EXTROVIS
Mathijs Steegstra, the Global Head of Scientific Affairs at EXTROVIS, oversees quality and regulatory affairs worldwide to ensure effective regulatory strategies. Prior to this role, Mathijs has held various positions such as Regulatory Affairs Director and EVP QA & DRA in pharmaceutical companies like Amneal Pharmaceuticals and MS PHARMA. With a background in MSc Pharmacy and Molecular Pharmacology from the University of Groningen, Mathijs has extensive experience in providing regulatory and quality consulting services for the pharma industry, managing global activities, and developing regulatory strategies for new products.
EXTROVIS
Extrovis is a fully integrated global pharmaceutical company with strong portfolio offering, comprising of Active Pharmaceutical Ingredients (APIs), Finished dosage forms (FDF) & Custom Pharmaceutical Services. Based in Switzerland, with global presence in North America, India and South America, we are supported by strong network to deliver products across geographies. Our state-of-the-art manufacturing facilities and R&D centers comply with highest international quality standards with accreditions from the USFDA, PMDA, EU and other global regulatory bodies. Our contributions in the area of education and health to financially under privileged reinforces our social commitment. Our mission is to become a reliable partner by offering high quality APIs, FDFs, custom pharmaceutical services and delivering value to our customers, stake holders and patients. Backed by our EXTROrdinary VISion, we have our eyes set on becoming a leading pharmaceutical company in the world.